CA2400803A1 - Croissance oculaire et antagonistes nicotiniques - Google Patents

Croissance oculaire et antagonistes nicotiniques Download PDF

Info

Publication number
CA2400803A1
CA2400803A1 CA002400803A CA2400803A CA2400803A1 CA 2400803 A1 CA2400803 A1 CA 2400803A1 CA 002400803 A CA002400803 A CA 002400803A CA 2400803 A CA2400803 A CA 2400803A CA 2400803 A1 CA2400803 A1 CA 2400803A1
Authority
CA
Canada
Prior art keywords
nicotinic
eye
nicotinic antagonist
antagonist
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400803A
Other languages
English (en)
Inventor
Richard A. Stone
Jon M. Lindstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400803A1 publication Critical patent/CA2400803A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une méthode consistant à administrer au plan oculaire des doses efficaces au plan thérapeutique d'un antagoniste nicotinique propre à réguler la croissance oculaire postnatale et à empêcher l'apparition d'une myopie.
CA002400803A 2000-01-18 2001-01-18 Croissance oculaire et antagonistes nicotiniques Abandoned CA2400803A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17687500P 2000-01-18 2000-01-18
US60/176,875 2000-01-18
PCT/US2001/001692 WO2001052832A1 (fr) 2000-01-18 2001-01-18 Croissance oculaire et antagonistes nicotiniques

Publications (1)

Publication Number Publication Date
CA2400803A1 true CA2400803A1 (fr) 2001-07-26

Family

ID=22646232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400803A Abandoned CA2400803A1 (fr) 2000-01-18 2001-01-18 Croissance oculaire et antagonistes nicotiniques

Country Status (10)

Country Link
EP (1) EP1272170A1 (fr)
JP (1) JP2003520228A (fr)
KR (1) KR20020081260A (fr)
CN (1) CN1418095A (fr)
AU (1) AU775516B2 (fr)
CA (1) CA2400803A1 (fr)
HK (1) HK1052464A1 (fr)
MX (1) MXPA02007039A (fr)
RU (1) RU2002120485A (fr)
WO (1) WO2001052832A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080081175A (ko) * 2005-12-19 2008-09-08 코멘티스, 인코포레이티드 안구 투여를 위한 국소 메카밀라민 제형 및 그것의 사용
FI20075498A (fi) 2007-06-29 2008-12-30 Eero Castren Menetelmä amblyopian hoitamiseksi masennuslääkkeillä
CN115645536A (zh) 2017-03-06 2023-01-31 坪田实验室股份有限公司 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033775T2 (de) * 1989-06-21 2001-11-15 Univ Pennsylvania Verwendung eines Muskarinantagonists zur Herstellung eines Medikaments für die Behandlung und Regulierung der Augenentwicklung
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method

Also Published As

Publication number Publication date
CN1418095A (zh) 2003-05-14
AU775516B2 (en) 2004-08-05
RU2002120485A (ru) 2004-04-10
MXPA02007039A (es) 2003-09-25
AU3096901A (en) 2001-07-31
WO2001052832A1 (fr) 2001-07-26
EP1272170A1 (fr) 2003-01-08
KR20020081260A (ko) 2002-10-26
HK1052464A1 (zh) 2003-09-19
JP2003520228A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
Atkins et al. Region‐specific induction of ΔFosB by repeated administration of typical versus atypical antipsychotic drugs
AU2023206175A1 (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
US20220040126A1 (en) Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
Gustilo et al. Evidence that nerve growth factor influences recent memory through structural changes in septohippocampal cholinergic neurons
US20110081428A1 (en) Use of thioflavin-like compounds to increase life span and/or health span
US20060264508A1 (en) Modulation of ocular growth and myopia by gaba drugs
US20030096831A1 (en) Ocular growth and nicotinic antagonists
Nargeot et al. Molecular basis of the diversity of calcium channels in cardiovascular tissues
US20210330646A1 (en) Fascin binding compounds for spinogenesis
AU775516B2 (en) Ocular growth and nicotinic antagonists
US20080311578A1 (en) System for screening eukaryotic membrane proteins
WO2008079980A1 (fr) Inhibiteurs de la protéine kinase c-delta pour le traitement du glaucome
BRPI0408749B1 (pt) uso do antagonista de vegf vegfr1r2-fc delta c1(a)
KR20230128037A (ko) Er형 미스센스 돌연변이를 갖는 환자에서, c형 니만픽병의 치료를 위한 아리모클로몰
EP3226883B1 (fr) Compositions pour le traitement de maladies dégénératives de la rétine
KR102124845B1 (ko) 근력증진제로서 stim2 저해제의 용도
IL303969A (en) ugh
Kieselbach et al. Elevated levels of substance P in intraocular fluid in proliferative vitreoretinopathy
US20240050427A1 (en) Treatments for obsessive compulsive disorder
US20050014170A1 (en) Effect of BDNF genotype on hippocampal function and verbal memory and risk for schizophrenia
US20040266677A1 (en) Method of diagnosing and treating lens illnesses using human HSF4 gene and coded product thereof
US20090048146A1 (en) Use of agents that upregulate crystallin expression in the retina and optic nerve head
US20080226653A1 (en) Inhibition of Platelet Aggregation
JP2004517046A (ja) 医薬
JP2016520610A (ja) 網膜変性疾患の治療のための組成物及び方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead